• Home >
  • Vital Signs The Analyst's Perspective - April 2016 Issue

Vital Signs The Analyst's Perspective - April 2016 Issue

24-May-2016  /  Research Code: 9A35-00-4B-00-00  /  SKU: HC02640-GL-MR_18576  /  
Region: Global

USD 450.00

* Required Fields

USD 450.00

PAY BY INVOICE

Be the first to review this product

This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.

Table of Contents

Vital Signs The Analyst's Perspective - April 2016 IssueVital Signs - April 2016 IssueApril 2016 Issue




Keyword1

Keyword2

Keyword3

Related Research

Innovations in Implantable Devices, Anti-microbial Textiles, 3D Bioprinting, Cardiovascular Devices, and Bone Grafts

Release Date : 15-Jun-18

Region : Global

Innovations in Chemotherapy Personalization, Cell Transplants, Multi-drug Resistance Studies, and Adult Stem Cell Regeneration

Release Date : 08-Jun-18

Region : Global

Technology Companies to Action--Point-of-care Diagnosis of Brain Injury

Release Date : 06-Jun-18

Region : Global

Recent Advances in Targeted Therapies

Release Date : 01-Jun-18

Region : Global

Technology Companies to Action--Novel Selective Inhibitors Addressing Neurologic and Endocrine System Diseases

Release Date : 31-May-18

Region : Global

Why Frost & Sullivan

Vision & Strategy

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Brand & Demand

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Technology & IP

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

Global Prespective

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.